Literature DB >> 7857277

The role of reactive oxygen intermediates in osteoclastic bone resorption.

T J Hall1, M Schaeublin, H Jeker, K Fuller, T J Chambers.   

Abstract

Osteoclasts have been shown to produce reactive oxygen intermediates (ROI) and it has been suggested that ROI are involved in the process of bone resorption. ROI have also been shown to play a central role in the activation of the multisubunit transcription factor NF-kappa B that enhances the transcription of genes encoding defence and signaling proteins. Therefore, we have assessed the effect of pyrrolidine dithiocarbamate (PDTC), an oxygen-radical scavenger and metal chelator that is a selective and potent inhibitor of NF-kappa B activation, on osteoclastic bone resorption in the bone slice assay. PDTC (0.001-0.1 mM) dose-dependently and non-cytotoxically inhibited osteoclast activity with an IC50 of 0.01 mM. PDTC (0.01 mM) caused no change in the ratio of resorption pit area to resorption pit depth as measured by Lasertec confocal microscopy, indicating that ROI are not involved in the resorptive process per se. This view is supported by time-course studies showing that addition of PDTC or N-acetyl cysteine (NAC; an ROI scavenger, but not metal chelator), 6 hr after the start of the assay had no significant effect on subsequent bone resorption. Desferal (100 microM), a chelator of iron and other metal ions, had no significant effect on bone resorption, indicating (along with the results with NAC) that ROI-scavenging rather than metal chelation is responsible for inhibition of osteoclastic bone resorption by PDTC. Taken together these results indicate that ROI produced by osteoclasts in the bone slice assay are not involved in the process of bone resorption, but are important during osteoclast activation for bone resorption, possibly being involved in activation of the transcription factor NF-kappa B.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7857277     DOI: 10.1006/bbrc.1995.1184

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species.

Authors:  Ho Jin Moon; Sung Eun Kim; Young Pil Yun; Yu Shik Hwang; Jae Beum Bang; Jae Hong Park; Il Keun Kwon
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

Review 2.  Molecular aspects of osteoclast function.

Authors:  T J Hall; T J Chambers
Journal:  Inflamm Res       Date:  1996-01       Impact factor: 4.575

3.  Zinc stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation.

Authors:  Masayoshi Yamaguchi; M Neale Weitzmann
Journal:  Mol Cell Biochem       Date:  2011-05-01       Impact factor: 3.396

4.  The intact strontium ranelate complex stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation.

Authors:  Masayoshi Yamaguchi; M Neale Weitzmann
Journal:  Mol Cell Biochem       Date:  2011-08-27       Impact factor: 3.396

5.  Exogenous regucalcin stimulates osteoclastogenesis and suppresses osteoblastogenesis through NF-κB activation.

Authors:  Masayoshi Yamaguchi; M Neale Weitzmann; Tomiyasu Murata
Journal:  Mol Cell Biochem       Date:  2011-08-14       Impact factor: 3.396

6.  2-mercaptoethanol restores the ability of nuclear factor kappa B (NF kappa B) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC). Evidence for oxidation of glutathione in the mechanism of inhibition of NF kappa B by PDTC.

Authors:  P Brennan; L A O'Neill
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

Review 7.  Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases.

Authors:  Danielle A Callaway; Jean X Jiang
Journal:  J Bone Miner Metab       Date:  2015-03-26       Impact factor: 2.626

8.  Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: is RANKL/RANK signalling really important?

Authors:  J Costa-Rodrigues; C A Teixeira; M H Fernandes
Journal:  Clin Exp Metastasis       Date:  2011-04-09       Impact factor: 5.150

9.  Suppression of NF-κB activation by gentian violet promotes osteoblastogenesis and suppresses osteoclastogenesis.

Authors:  M Yamaguchi; T Vikulina; J L Arbiser; M N Weitzmann
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

10.  Inhibition of human in vitro osteoclastogenesis by Equisetum arvense.

Authors:  J Costa-Rodrigues; S C Carmo; J C Silva; M H R Fernandes
Journal:  Cell Prolif       Date:  2012-12       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.